Missense mutations in the PML/RARα ligand binding domain in ATRA- resistant As2O3 sensitive relapsed acute promyelocytic leukemia

Haematologica

Volumn 84, Issue 11, 1999, Pages 963-968

  Marasca, Roberto ^a   Zucchini, Patrizia ^a   Galimberti, Sara ^c   Leonardi, Giovanna ^a   Vaccari, Paola ^a   Donelli, Amedea ^a   Luppi, Mario ^a   Petrini, Mario ^b   Torelli, Giuseppe ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c NONE

Author keywords

Acute promyelocytic leukemia; Arsenic trioxide; ATRA resistance; Missense point mutations; PML RAR

Indexed keywords

AMINO ACID; ARSENIC TRIOXIDE; DNA FRAGMENT; RETINOIC ACID;

AMINO ACID SUBSTITUTION; ARTICLE; CHROMOSOME TRANSLOCATION; HUMAN; LIGAND BINDING; MISSENSE MUTATION; PROMYELOCYTIC LEUKEMIA; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTINEOPLASTIC AGENTS; ARSENICALS; BINDING SITES; BONE MARROW; CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIGANDS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRETINOIN;

EID: 0032753459     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Longo L, Pandolfi PP, Biondi A, et al. Rearrangements and aberrant expression of the retinoic acid receptor α gene in acute promyelocytic leukemia. J Exp Med 1990; 172:1571-5.
2. Miller WH Jr, Warrell RP Jr, Frankel SR, et al. Novel retinoic acid receptor-α transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst 1990; 82:1932-3.
3. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66:663-74.
4. Brown D, Kogan S, Lagasse E, et al. A PML/RARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94:2551-6.
5. Breitman TR, Collins SJ, Keene BR. Terminal differentiating of promyelocytic leukemia cells in primary culture in response to retinoic acid. Blood 1981; 57: 1000-4.
6. Warrell RP, Frankel SR, Mille W, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid). N Engl J Med 1991; 324:1385-92.
7. Nervi C, Poindexter EC, Grignani F, et al. Characterization of the PML-RARα chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. Cancer Res 1992; 52:3687-92.
8. Benedetti L, Levin AA, Scicchitano BM, et al. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 1997; 90:1175-85.
9. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83:10-25.
10. Castaigne S, Chomienne C, Daniel MT, et al. All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76:1704-9.
11. Fenaux P, Le Deley MC, Castaigne S, et al. The European APL 91 Group. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82:3241-9.
12. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia. Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) pilot study. Blood 1996; 91:3093-102.
13. Lefebvre P, Thomas G, Gourmel B, et al. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 1991; 5: 1054-8.
14. Delva L, Cornic M, Balitrand N, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro sensitivity and cellular retinoid binding protein levels in leukemic cells. Blood 1993; 82:2175-81.
15. Kizaki M, Ueno H, Yamazoe Y, et al. Mechanisms of retinoid resistance in leukemia cells: possible role of cytochrome p-450 and P-glycoprotein. Blood 1996; 87:725-33.
16. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. A retinoid-resistant acute promyelocytic subclone expresses a dominant negative PML-RARα mutation. Blood 1997; 89:4282-9.
17. Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998; 92:374-82.
18. Ding W, Li Y-P, Mobile LM, et al. Leukemic cellular retinoid acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172-83.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate phenolchloroform extraction. Anal Biochem 1987; 162:156-9.
20. Diverio D, Riccioni R, Pistilli A, et al. Improved rapid detection of the PML/RARα fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10:1214-6.
21. Borrow J, Goddard AD, Gibbons B, et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARα and RARα-PML fusion transcripts. Br J Haematol 1992; 82:529-40.
22. Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of the residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992; 340:1437-8.
23. Galimberti S, Papineschi F, Carmignani A, Testi R, Fazzi R, Petrini M. Arsenic and all-trans retinoic acid association as induction therapy before auto-graft in a case of relapsed, resistant, secondary acute promyelocytic leukemia. Bone Marrow Transplant 1999; 24: 345-8.
24. Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330:624-9.
25. Muindi J, Frankel S, Miller WJ, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 1992; 79:299-307.
26. Muindi J, Young C. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human microsomes genetically enriched in specific cytochrome P-450 isoforms. Cancer Res 1992; 53:1226-9.
27. Renaud JP, Rochel N, Ruff M, et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 1995; 378:681-9.
28. Lamour F, Lardelli P, Apfel C. Analysis of the ligand-binding domain of human retinoic acid receptor α by site-direct mutagenesis. Mol Cell Biol 1996; 16:5386-92.
29. Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-60.
30. Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-8.
31. Nason-Burchenal K, Allopenna J, Begue A, Stehelin D, Dmitrovsky E, Martin P. Targeting of PML/RARα is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 1998; 92:1758-67.
32. Shao W, Fanell M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia. J Natl Cancer Inst 1998; 90:124-33.
33. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17:61-70.
34. Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, Naoe T. Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARα and its down-regulation in acute promyelocytic leukemia. Leukemia 1997; 11:1950-6.